We are live on ! Find out more
NPCE icon

Neuropace

100 hedge funds and large institutions have $406M invested in Neuropace in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 37 increasing their positions, 30 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 4

52% more capital invested

Capital invested by funds: $268M → $406M (+$138M)

25% more funds holding

Funds holding: 80100 (+20)

23% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 30

0.53% more ownership

Funds ownership: 78.43%78.96% (+0.53%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
100
Holders Change
+20
Holders Change %
+25%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
26
Increased
37
Reduced
30
Closed
4
Calls
$20K
Puts
Net Calls
+$20K
Net Calls Change
+$37K
Name Holding Trade Value Shares
Change
Change in
Stake
DSCM
101
Divisadero Street Capital Management
Florida
-$3.02M -292,792 Closed
RS
102
R Squared
Hong Kong
-$133K -12,927 Closed
AllianceBernstein
103
AllianceBernstein
Tennessee
-$117K -11,310 Closed
HI
104
Harbour Investments
Wisconsin
-$2.3K -223 Closed

NPCE Hedge Fund Activity: Q4 2025 in Review

100 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q4 2025, worth a combined $406M — up 52% from $268M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new NPCE positions and 4 closed out — a net gain of 22 holders — while 37 added to existing stakes and 30 trimmed.

The largest buyer was Driehaus Capital Management, adding an estimated $7.65M. The largest seller was Armistice Capital, cutting an estimated $6.77M.

  • 100 institutional investors held Neuropace (NPCE) as of Q4 2025, up from 80 in Q3 2025.
  • Funds reported $406M of Neuropace stock for Q4 2025, up 52% quarter-over-quarter.
  • 26 funds opened new Neuropace positions in Q4 2025 and 4 closed out, a net change of +22 holders.
  • The largest Neuropace buyer in Q4 2025 was Driehaus Capital Management, an estimated $7.65M added.
  • The largest Neuropace seller in Q4 2025 was Armistice Capital, an estimated $6.77M sold.

Based on aggregated 13F filings for Q4 2025.